Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Muschitz, C; Kocijan, R; Pahr, D; Patsch, JM; Amrein, K; Misof, BM; Kaider, A; Resch, H; Pietschmann, P.
Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Calcif Tissue Int. 2015; 96(6): 477-489.
Doi: 10.1007/s00223-015-0003-8
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Amrein Karin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The pathomechanism of male idiopathic osteoporosis (MIO) differs from postmenopausal osteoporosis with regard to alterations in osteoblast activity. We evaluated intravenous ibandronate (IBN) in 25 MIO patients with fragility fractures in a prospective, monocentric, single-arm, and open-label study for 24 months. The impact and changes of sclerostin (Scl), Dickkopf-1 (DKK-1), CTX, and PINP were examined. Additionally, volumetric cortical, trabecular and areal bone mineral density (BMD), trabecular bone score (TBS), and finite element analyses (FEA) were evaluated. Compared to baseline, median Scl levels were increased after 1 month (Δ 121%, p < 0.0001) and remained elevated for 12 months. DKK-1 decreased (p < 0.001) to a lesser extent until month 9 with values comparable to baseline at study endpoint. Early changes (baseline-month 1) of Scl negatively correlated with early changes of DKK-1 (-0.72), CTX (-0.82), and PINP (-0.55; p < 0.005 for all). The overall changes over the 24 months study period of Scl negatively correlated with decreased CTX (-0.32) and DKK-1 levels (-0.57, p < 0.0001 for both); CTX and PINP changes positively correlated at each time point (p < 0.001). Volumetric hip BMD increased by 12 and 18%, respectively (p < 0.0001 for both). Cross-sectional moment of inertia and section modulus for total hip significantly improved (p < 0.05 for all). Areal BMD at total hip, spine, and TBS increased. FEA displayed an increase in bone strength both in the hip (17%) and vertebrae (13%, all p < 0.0001) at anatomical sites susceptible for fragility fracture. IBN increases Scl and improves cortical and trabecular bone strength with early and ongoing vigorous suppression of bone resorption.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Bone Density - drug effects
- Bone Density Conservation Agents - therapeutic use
- Bone Morphogenetic Proteins - blood
- Bone Remodeling - drug effects
- Diphosphonates - therapeutic use
- Enzyme-Linked Immunosorbent Assay -
- Finite Element Analysis -
- Genetic Markers -
- Humans -
- Ibandronic Acid -
- Male -
- Middle Aged -
- Osteoporosis - blood
- Osteoporosis - drug therapy
- Find related publications in this database (Keywords)
- Antiresorptive agents
- Ibandronate
- Male osteoporosis
- Sclerostin
- Bone turnover marker
- Finite element analysis